Resources
The National Pharmaceutical Council (NPC) is a health policy research organization dedicated to the advancement of good evidence and science, and to fostering an environment in the United States that supports medical innovation.
Filter by:
Topic
Topic
- Accountable Care Organizations
- Alternative Payment Models
- Biopharmaceutical Innovation
- Bundled Payments
- (-) Clinical Pathways
- Decision Frameworks
- Elements of Value
- Evidence for Decision Making
- (-) Formulary/Benefit Design
- Formulary Development
- Good Practices for Evidence
- Health Care Quality Measures
- Health Spending
- Health Spend Management
- High-Deductible Health Plans
- Impact on Outcome & Spending
- Individual Treatment Effects & Personalized Access
- IRA Implementation
- Low-Value Care
- Pandemic Response
- Patient Cost Sharing
- Paying for Cures
- Policy & Regulatory Barriers
- Real-World Data
- Real-World Evidence
- Regulatory Barriers & Challenges
- Understanding Health Spending
- (-) Utilization Management & Step Therapy
- Value-Based Contracts
- Value-Based Insurance Design
- Value Assessment
- Value Assessment Frameworks
- Value Assessment Methods
Resource Type
Resource Type
Audience
Audience
Display Only
Showing 62 Results
Drug Innovations Are Delivering for Patients. We Need Innovation in How They’re Paid For.
In a commentary for PharmaBoardroom, NPC's John M. O’Brien explains why we need a focused effort from all health care stakeholders to innovate on how we pay for vital medicines.
Rethinking Benefit Design: Eliminating Inefficient Hurdles
Reforming health benefits by overhauling existing utilization management practices and adjusting patient cost-sharing to incentivize high-value care would help achieve more affordable, patient…
Why Drug Rebates Aren’t Working for Patients
During a recent webinar, NPC President and CEO John M. O'Brien discusses how the Medicare Part D rebate system creates barriers to affordable care for patients.
Limited Role of Patient Input in Specialty Drug Coverage Policies
A new study in JMCP found that patient input is rarely sought for coverage policies – although plans had processes to engage physicians and medical societies when developing coverage policies, no…
Missing: Patient Input in Drug Coverage Policy
A new study by NPC and the Center for the Evaluation of Value and Risk in Health at Tufts Medical Center found that health insurance plans do not ask patients for input when developing specialty drug…
Affordability Is About More Than Drug Prices
A research survey from NPC and Xcenda found that potential government involvement in drug pricing would be unlikely to increase patient affordability.
NPC’s New Leader: Merging Research and Data with Real-World Experience
NPC Board Chair Michael Ryan says John M. O’Brien’s arrival as the new president and CEO of NPC reinforces a vital role the biopharmaceutical industry can play in the ongoing debate about health care…
Savvy Employers Alter Status Quo to Address Drugs, Deductibles and Disincentives for Treatment
Thanks to an IRS rule, high-deductible health plans with health savings accounts can now cover an expanded list of preventive services and drugs before patients meet their plan’s annual out-of-pocket…
Stakeholders Find Step Therapy Should Be Evidence-Based, Flexible and Transparent: Assessing Appropriateness Using a Consensus Approach
Stakeholders disagree on when step therapy is appropriate, but agree on a set of criteria about how to develop, implement, communicate, safeguard and evaluate step therapy protocols.
If You Must Do Step Therapy, Do It Right
Finding consensus among health care stakeholders is never easy, and that is certainly true when it comes to the use of care management tools. But there are areas of agreement, especially if we focus…
Racial and Socioeconomic Disparities: Ignoring Inequitable Benefit Design Is Not an Option
In a new commentary published in BenefitsPro, Kimberly Westrich, NPC Vice President for Health Services Research, and Bruce Sherman, MD, medical advisor for the National Alliance of Healthcare…
Health Plan Enrollment May be Open, but Drug Coverage Is Still a Black Box for Many People
Most people choose coverage based mainly on the price – the health care premiums and deductibles. But a narrow focus on health care costs overlooks the overall quality of the health plan. Consumers…
AARDA’s Randy Rutta Talks Step Therapy
In this Q&A, Randy Rutta, AARDA’s President and CEO, talks about his organization’s efforts to raise awareness about step therapy and opportunities for patient-centered reforms.
Lessons from COVID-19: Step Therapy Should Not Be a Barrier to Patient Access
Step therapy requires patients to try a clinically recognized, lower cost first-line therapy before receiving reimbursement for an alternative therapy prescribed by the physician and can delay access…
Principles for Sound Pharmacy and Therapeutics Practices: What’s Next
AMCP's Partnership Forum, “Principles for Sound Pharmacy and Therapeutics (P&T) Practices: What’s Next?” focused on the current state of P&T committees, challenges faced by these committees…
Updated Tools Developed to Communicate High-Quality Information About New Treatments and Inform Health Plan Coverage and Reimbursement
NPC said that with the release of the new AMCP Format for Formulary Submissions, biopharmaceutical manufacturers and health plans will have a practical guide to exchange clinical and economic…
Little Consistency in Evidence Cited by Commercial Health Plans for Specialty Drug Coverage
Evidence cited by payers in coverage decisions for specialty medicines varies significantly, with health plans only citing the same study in 15% of health plan coverage policies for a given drug and…
U.S. Care Pathways: Continued Focus on Oncology and Outstanding Challenges
A peer-reviewed study assessed changes in development, implementation, and evaluation of care pathways, and reviewed the latest evidence on integration of pathways with value-based care initiatives…
How Can We Elevate the Patient Voice in Value-Based Payment for Oncology?
A new study from the National Pharmaceutical Council (NPC) and Discern Health sheds new light on progress in making value-based reimbursement mechanisms, like accountable care, patient-centered.
Case Study Shows Benefits of Engaging Employees in Health Benefit Design
As open enrollment season for health insurance gets underway, a new case study shows that employees who are meaningfully engaged in deliberating and designing their health care benefits may have a…